Sign In
Buy STIM
$1.20
-0.0300 (-2.44%)
At Close: Jun 22, 2026
Neuronetics Announced as a Winner by 2022 Merit Awards for HealthCare in the Patient Care Category
01:32pm, Monday, 05'th Dec 2022 GlobeNewswire Inc.
NeuroStar’s technology once again recognized as an effective non-drug treatment for patients NeuroStar’s technology once again recognized as an effective non-drug treatment for patients
Neuronetics: Numerous Expansion Opportunities Mean An Outperforming Stock
02:07pm, Monday, 28'th Nov 2022
The high prevalence of major depressive disorder creates the need for Neuronetics' NeuroStar Advanced Therapy System. Neuronetics is valued below its industry, leaving plenty of room to the upside for
Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference
04:30pm, Monday, 21'st Nov 2022
MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve th
New Strong Buy Stocks for November 16th
12:27pm, Wednesday, 16'th Nov 2022 Zacks Investment Research
ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.
New Strong Buy Stocks for November 16th
09:02am, Wednesday, 16'th Nov 2022
ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.
Neuronetics Announces NeuroStar® Advanced Therapy for Mental Health System Innovations
01:33pm, Monday, 14'th Nov 2022 GlobeNewswire Inc.
Enhancements further establish the Company’s leadership position as the top transcranial magnetic stimulation therapy Enhancements further establish the Company’s leadership position as the top tr
Neuronetics, Inc. (STIM) Q3 2022 Earnings Call Transcript
01:00pm, Friday, 11'th Nov 2022
Neuronetics, Inc. (NASDAQ:STIM ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sullivan - President and Chief Executive Officer
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01:04am, Thursday, 10'th Nov 2022 GlobeNewswire Inc.
MALVERN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve
Neuronetics (STIM) Reports Q3 Loss, Tops Revenue Estimates
01:45pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Neuronetics (STIM) delivered earnings and revenue surprises of 36.36% and 11.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
10:35pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Glaukos (GKOS) delivered earnings and revenue surprises of 15.09% and 4.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics Announced as Winner by 2022 Merit Awards for Technology
12:31pm, Monday, 31'st Oct 2022 GlobeNewswire Inc.
NeuroStar technology is acknowledged for its innovation and accessibility as a non-drug treatment for mental health NeuroStar technology is acknowledged for its innovation and accessibility as a non-d
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
10:05pm, Thursday, 27'th Oct 2022 Zacks Investment Research
DexCom (DXCM) delivered earnings and revenue surprises of 16.67% and 2.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics Announces Updated TMS Coverage Policies That Will Expand Patient Access to NeuroStar TMS Therapy for Mental Health
02:31pm, Tuesday, 25'th Oct 2022 GlobeNewswire Inc.
Published and Proposed Medicare Coverage through CGS and NGS MACs Will Reduce Number of Medication Trials, Leading to Increased Eligibility for TMS Published and Proposed Medicare Coverage through CGS
Neuronetics to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call
08:30am, Tuesday, 25'th Oct 2022
MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve th
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
09:09am, Thursday, 29'th Sep 2022 Benzinga
Gainers
PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The tria
